This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
T

ASCO® 2024 Insights: "KEYNOTE-361 Trial - Quantitative ctDNA Assessment in Patients With Advanced UC Treated With Pembro or Platinum-Based Chemo"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Thomas Powles
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Thomas Powles
146 views
June 7, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

20:25
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

2024 ASCO® Annual Meeting Insights Hub: GU Videos

22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
09:00
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "CHAARTED2 Trial - Cabazitaxel + Abiratero…

Feat. C. Kyriakopoulos
View All

Related Content

AUTOPLAY
International Urology Cancer Summit - IUCS

Second International Urology Cancer Summit

Fri, Sep 27, 2024
14:16
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Mes…

Feat. E. Efstathiou
16:05
Insights from 2024 ASCO® GU Annual Meeting

Recent GU Developments and Their Clinical Implications

Feat. T. Powles, B. Rini
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
09:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton
09:14
Robert Dreicer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

15:58
Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
17:32
Kriti Mittal

Current Updates in Urothelial Cancer: Clinical Implications for Prac…

09:45
Northwestern Medicine Oncology and Hematology

Differences Between Urologists and Medical Oncologists in the Manage…

Feat. W. Catalona
14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
22:07
Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

Feat. C. Sternberg
19:30
Scripps Health

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Feat. P. Grivas
06:01
ecancer

ESMO 2023 Insights: "Phase 3 EV-302 Trial - Evaluating the Comb…

Feat. T. Powles
06:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Systemic Treatments in Favorable and Very…

Feat. M. Zarba
10:19
University of Colorado Cancer Center

NCCN Guidelines Updates for the Treatment of Metastatic Urothelial C…

Feat. T. Flaig
30:03
UCSF School of Medicine

Recent Advances in Advanced Urothelial Cancers: Time for a New Stand…

Feat. T. Friedlander
11:29
Oncology Data Advisor

Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…

Feat. T. Powles
09:40
UCSF School of Medicine

Trastuzumab Deruxtecan Approval for Metastatic HER2+ Bladder Cancer

Feat. V. Koshkin